Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • UK
  • Clinic Portal Login
  • +44 (0)20 8068 8176
  • Request Information
  • +44 (0)20 8068 8176
United KingdomUnited Kingdom
  • Part of brands: |
  • Reproductive Health
    • Specialists
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • PGT-A with ploidy
      • EMBRACE
      • PGT-SR
      • PGT-M
      • Infertility Panels
      • POC PORTFOLIO
      • NACE (NIPT)
      • SAT
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
  • User Manual
  • Send a Sample
  • Academy
Genomics Precision Diagnostic > Oncology > Oncology Comprehensive Inherited Cancer

Comprehensive Inherited

Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies, it is of special importance to identify these patients because, unlike patients with sporadic cancers, they require special, long-term care as their predisposition can cause them to develop certain tumors at a relatively early age.
The Igenomix Comprehensive Inherited Cancer Precision Panel provides a comprehensive analysis of the most common hereditary cancer syndromes using next-generation sequencing (NGS) to fully understand the spectrum of relevant cancer predisposition genes.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies, it is of special importance to identify these patients because, unlike patients with sporadic cancers, they require special, long-term care as their predisposition can cause them to develop certain tumors at a relatively early age. These cancers can arise in the lungs, kidneys, liver, pancreas, skin, eyes, heart. Most hereditary cancers are associated with a “germline mutation” that will be present in every cell of the human body.Identification of patients at risk of inherited cancer susceptibility is dependent upon the ability to characterize genes and alterations associated with increased cancer risk as well as gathering a detailed personal and family history aiding in the identification of the mode of inheritance as well as other family members at risk of suffering from this susceptibility. Most hereditary cancer syndromes follow an autosomal dominant inheritance, and the penetrance is high.
  • The Igenomix Comprehensive Inherited Cancer Precision Panel provides a comprehensive analysis of the most common hereditary cancer syndromes using next-generation sequencing (NGS) to fully understand the spectrum of relevant cancer predisposition genes.

Indication

The Igenomix Comprehensive Inherited Caner Precision Panel is indicated as a screening and diagnostic test in those cases where there are: 

  • Multiple relatives on the same side of the family with the same or related forms of cancer  
  • Cancer at an early age  
  • Early presentation of an aggressive cancer type  
  • Multiple primary cancers in an individual 

Clinical Utility

The clinical utility of this panel is: 

  • Early and accurate genetic diagnosis allowing the most appropriate clinical management of a patient with personal or family history suggestive of a hereditary cancer syndrome. 
  • Intensified surveillance and participation on early detection programmes for cancer prevention. 
  • Early initiation of treatment or surgical intervention. 
  • Risk assessment of asymptomatic family members according to the mode of inheritance and genetic counselling of relatives. 

Genes & Diseases

Methodology

References

See scientific referrals

LaDuca et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med 22, 407–415 (2020). https://doi.org/10.1038/s41436-019-0633-8  

Breast Cancer Association Consortium, Dorling L, et al. Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women. N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa1913948. Epub ahead of print. PMID: 33471991. 

Rahner, N., & Steinke, V. (2008). Hereditary cancer syndromes. Deutsches Arzteblatt international, 105(41), 706–714. https://doi.org/10.3238/arztebl.2008.0706  

Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., Burt, R. W., & American College of Gastroenterology (2015). ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. The American journal of gastroenterology, 110(2), 223–263. https://doi.org/10.1038/ajg.2014.435  

Li et al. (2020). Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics In Medicine, 22(7), 1142-1148. doi: 10.1038/s41436-020-0783-8  

Garber, J. E., & Offit, K. (2005). Hereditary cancer predisposition syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(2), 276–292. https://doi.org/10.1200/JCO.2005.10.042  

National Comprehensive Cancer Network. (2021). https://www.nccn.org/professionals/physician_gls/default.aspx#detection  

descargar

Detail description

Download

Request Information


WE GUIDE YOU Fertility Inherited diseases prevention Healthy pregnancy
Click to view our ISO: 15189 accreditation
OUR SERVICES Genetic solutions For patients Sending samples and documentation
ABOUT US About Igenomix Contact User manual Work with us
FOLLOW IGENOMIX
  020 8068 8176 Email us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country
[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy       Complaints form

Request Information

Copyright 2025 © UX Themes
  • Reproductive Health
    • Specialists
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • PGT-A with ploidy
      • EMBRACE
      • PGT-SR
      • PGT-M
      • Infertility Panels
      • POC PORTFOLIO
      • NACE (NIPT)
      • SAT
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
  • User Manual
  • Send a Sample
  • Academy
  • WooCommerce not Found
  • Newsletter
  • UK
  • Clinic Portal Login

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

United Kingdom
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.